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Introduction
P
atients with human immunodeficiency virus 
(HIV) are also likely to be at risk for other 
infectious  pathogens.  Coinfection  with  HIV  and 
hepatitis  B  virus  (HBV)  and/or  hepatitis  C  virus 
(HCV) is common because all of these diseases are 
spread  by  similar  routes  of  viral  transmission.  Of 
late, liver diseases due to chronic hepatitis B and 
C infection are becoming a leading cause of death 
and  decrease  life  expectancy  among  persons  with 
HIV infections worldwide (1). On the other hand, 
viral  hepatitis  complicates  the  clinical  course  and 
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Background  and  Aims:  Patients  with  human  immunodeficiency  virus  (HIV)  are  also  likely  to  be  at  risk  for  other 
infectious pathogens including hepatitis B (HBV) and C (HCV) viruses, which complicate the clinical course, management, 
and therapy. The literature on the prevalence of HBV/HCV coinfection with HIV in Iran is sparse. Hence this study was 
conducted to investigate this coinfection pattern and its risk factors in Isfahan, Iran. 
Methods: All of the HIV-infected patients attending clinics for acquired immune deficiency syndrome (AIDS) research and 
education in Isfahan province during the period of May 1998 through April 2007 were included in this cross-sectional study. 
After giving their informed consent, the patients were screened for hepatitis B surface antigen (HBsAg) and antibodies to 
hepatitis C virus (anti-HCV), and anti-HCV-positive cases were confirmed with the RIBA test.
The demographic data and information about risk behaviors were collected as well. Multivariate logistic regression was 
used to identify independent risk factors for HBV and HCV. 
Results: The subjects included 130 patients (128 males and 2 females) with a mean age of 50.23 ± 8.81 years. Most of the 
subjects were unemployed (61.5%) and single (56.2%). A history of imprisonment, , intravenous drug abuse, and high-risk 
sexual activity were reported by 83.7%, 83.5%, and 48% of the subjects, respectively. Coinfection with hepatitis viruses 
was observed in 78.5% of the subjects. Low levels of education, a history of imprisonment, and youth were the main risk 
factors for HCV/HIV coinfection (OR = 196, 114, and 0.9 respectively).
Conclusions: Our study showed that there is a high prevalence rate of HCV/HIV coinfection in Isfahan, Iran, with the 
major risk factor being a history of imprisonment.
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management, and may also adversely affect therapy, 
for  HIV  infection  (2).  The  evidence  has  shown 
that highly active antiretroviral therapy (HAART) 
effectively prevents AIDS, but this regimen does not 
suppress HCV (3). 
For these reasons, in the United States and Europe, 
the screening of all HIV-infected persons for HBV 
and HCV is recommended (4). Various international 
studies  have  been  conducted  to  demonstrate  the 
rate of coinfection with either HCV or HBV, and 
the results naturally vary according to country and 
subpopulation.(3).  Indeed,  the  prevalence  varies, 
depending  on  the  patient's  risk  factors  for  HIV 
acquisition  (1).  Few  studies  have  focused  on  the 
prevalence of coinfection with HIV and HBV and/or 
HCV in Iran. Hence, in this study we investigated the 
coinfection pattern of HBV and HCV among HIV-
infected patients and their risk factors in Isfahan, Iran 
to support the implementation of future strategies to 
improve national and international monitoring of 
this problem.
Materials and Methods
This  cross-sectional  study  was  approved  by 
the  Ethical  Committee  of  Isfahan  University  of 
Medical Sciences One hundred and thirty subjects 
were recruited from clinics for AIDS research and 
education and triangular clinics in Isfahan province 
(a province in central Iran) from May 1998 through 
April 2007. HIV confirmed by means of the enzyme-
linked immunosorbent assay (ELISA) (Diapro-Italy) 
and Western Blot (Immunogenetic, Germany) tests.
he triangular clinics in Iran make use of dedicated 
staff to deliver services such as harm reduction to drug 
abusers, to people who want to receive HIV counseling 
and testing, to people living with HIV/AIDS and 
their families, to high-risk populations, to patients 
with STDs, and to persons who have been exposed 
to  potentially  contaminated  bodily  fluids.  These 
clinics provide services both for prevention and care. 
Participation in the study was on a voluntary basis, 
and after obtaining informed consent, 5cc of venous 
blood  was  taken  from  each  subject.  Diagnosis  of 
HBV and HCV infection was made using the ELISA 
metho anti-HCV kit (Dia-pro Diagnostic Bioprobes 
s.r.l., third generation, Italy) and the HBsAg kit (Dia-
pro  Diagnostic  Bioprobes  s.r.l.  -Italy)  respectively. 
The anti-HCV positive subjects were confirmed with 
a  RIBA  test  (Immunogenetic,  Germany).  Among 
the  subjects,  one  patient,  a  responsible  physician, 
recorded  sociodemographic  information  including 
age,  marital  status,  employment  status,  history  of 
imprisonment, and high-risk behaviors (intravenous 
drug abuse and high-risk sexual activities). 
Descriptive  statistics  are  presented  in  Table  1 
with the means ± standard deviation or proportions 
for continuous or categorical variables, respectively. 
The  normal  distribution  of  continuous  variables 
was  validated  by  a  Kolmogorov-Smirnov  test, 
and  a  multivariate  logistic  regression  model  was 
used to obtain the risk factors for HBV and HCV. 
Data analyses were carried out with the Statistical 
Package for Social Sciences software (SPSS, version 
15).  P-values  <  0.05  were  considered  statistically 
significant. 
Results
The subjects included 128 male and 2 females. 
The mean age (with the normal distribution of age 
validated by a Kolmogorov-Smirnov test) was 50.23 ± 
8.81 years. The main demographic characteristics in 
the participants are presented in table 1.One hundred 
and  six  (83.5%)  of  the  subjects  were  intravenous 
drug abusers, and 61 (48%) had engaged in high-
risk sexual behavior. Forty subjects from these two 
groups (31.5%) showed both risk factors. None of 
the subjects admitted to homosexuality..Most types 
of sexual behavior besides that within the marital 
state  were  considered  unsafe,  Of  the  130  HIV-
infected patients, 102 (78.5%) were coinfected with 
one or both of the hepatitis viruses. 
According  to  the  laboratory  tests,  15  subjects 
(11.5%) were HBsAg positive, 100 (77%) were anti-
HCV positive, and 12 subjects (9.2%) from these 
Table 1. Demographic Characteristics of the HIV-
infected Subjects (n = 130).
Demographic Characteristics Number Percent
Gender
Male
Female
128
2
98.5
1.5
Occupation
Yes 50 38.5
No 80 61.5
Education
Illiterate 9 7
Elementary school 52 40.3
Secondary school 33 25.6
High school 10 7.8
Diploma 22 17.1
Academic education 3 2.3
Marital status
Not married 73 56.2
Married 37 28.5
Divorced 18 13.8
Widow 2 1.5
Prison History
Yes 108 83.7
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have also been reported in other studies (15, 20, 21). 
This may be due to higher-risk behaviors and lower 
awareness in young adults and the less educated. On 
the other hand, as young people are prone to high-
risk behavior, the results seem logical.
Although drug abuse has been the major route 
of  HIV  and  HCV  transmission  in  Iran  (3),  after 
adjusting  for  variables  in  multivariate  logistic 
regression analyses, intravenous drug abuse (IVDA) 
was not included as a significant risk factor for HCV/
HIV coinfection in our study. Additionally, in the 
present study, no risk factor was detected for HBV 
or  HBV/HCV  coinfection.  This  may  have  been 
a result of the low prevalence of HBV and HBV/
HCV  coinfection  in  our  subjects  or  simply  the 
small sample size. Also, because consultants in the 
clinics for AIDS research and education have been 
providing essential education about safe sex (such as 
the use of prophylactics), it is possible that the sexual 
transmission of HBV (the most important route for 
HBV transmission) has had limited scope in these 
patients.
There are several limitations to the present study 
that  require  consideration.  First,  the  study  was 
conducted with patients who attended the triangular 
and HIV/AIDS clinics and were not studied in a 
community setting, so we are unable to generalize 
our findings outside the study population. Second, 
we made little use of the polymerase chain reaction 
(PCR),  because  of  its  prohibitive  cost,  given  our 
limited resources. Some studies have demonstrated 
that in HIV-infected patients, testing only serological 
viral markers such as HBsAg, antibodies to hepatits 
B e antigen (anti-HBe) IgG, and anti-HCV, fails to 
identify the true prevalence of coinfection with HBV 
and HCV. The qualitative PCR for HBVDNA and 
HCVRNA detects coinfection in patients who are 
negative for serologic markers  (20). Third, because 
extramarital sexual activity is taboo in our country, it 
is possible that such behavior.was denied by some of 
our subjects out of fear of exposure.
Conclusions
This study shows that there is a high prevalence 
of  HCV/HIV  coinfection  in  Isfahan,  Iran  and 
that  being  in  prison  has  a  considerable  effect  on 
this  phenomenon.  Therefore  resources  should  be 
allocated for the prevention and treatment of HCV/
HIV coinfection. It would seem advisable to screen 
for  hepatitis  viruses  in  the  entire  HIV  infected 
population at the earliest possible time. Additionally, 
the provision of education for high-risk groups and 
for young people on the prevention and transmission 
of the infection should be should be considered as 
well.
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